Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million

Reuters
6 hours ago
April 22 (Reuters) - Mayne Pharma Group Ltd ::
*IN FY25, ANTICIPATES UNDERLYING EBITDA IN RANGE OF A$47 MILLION TO A$51 MILLION
*9-MONTHS UNAUDITED UNDERLYING EBITDA A$28.6 MILLION
*SIGNS AGREEMENT WITH SOL-GEL TECHNOLOGIES
*9-MONTHS REVENUE A$300 MILLION
*TERMS OF DEAL ARE US$10 MILLION IN CASH AT CLOSING AND AN ADDITIONAL US$6 MILLION IN CASH SIX MONTHS THEREAFTER
*Further company coverage: MYX.AX
* ((Reuters.Briefs@thomsonreuters.com;))

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 22-APR-202501:33:07 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10